Vicarious Surgical (RBOT) Fundamental Analysis: Revenue, Earnings & Valuation

0.31 / 10

Underperform

Analysis concludes poor fundamental quality (0.3/10). Favorable components: Profit-MV and Net income-Revenue, whereas limitations surface in Net profit margin (%) and Net profit / Total operating revenue (%). Investment recommendation: prudent.

Analysis Checks(4/10)

Total operating revenue (YoY growth rate %)

Value78.31

Score0/3

Weight29.95%

1M Return-6.17%

Net cash flow from operating activities / Operating revenue (%)

Value-1506.20

Score0/3

Weight35.22%

1M Return-7.26%

Profit-MV

Value0.43

Score2/3

Weight-8.37%

1M Return1.29%

Net income-Revenue

Value-0.16

Score2/3

Weight-3.68%

1M Return0.59%

Net profit margin (%)

Value-2958.68

Score0/3

Weight36.18%

1M Return-7.54%

Operating revenue (YoY growth rate %)

Value92.51

Score0/3

Weight30.59%

1M Return-6.45%

EBIT / Total operating revenue (%)

Value-3041.03

Score0/3

Weight34.25%

1M Return-7.07%

Asset-MV

Value-0.49

Score3/3

Weight-79.70%

1M Return10.29%

Net profit / Total operating revenue (%)

Value-2155.42

Score0/3

Weight35.62%

1M Return-7.40%

Cash-MV

Value-0.07

Score2/3

Weight-10.06%

1M Return1.56%

Is RBOT undervalued or overvalued?

RBOT scores 0.31/10 on fundamentals and holds a Premium valuation at present. Backed by its -130.51% ROE, 0.00% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and 11.64% earnings growth, these metrics solidify its Underperform investment rating.

RBOT(Delisted)

Analysis Checks(4/10)